ABT - Company ID 0000001800
ABBOTT LABORATORIES (ABT) reported revenue of $44.33B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $44.33B | +5.7% |
| FY 2024 | $41.95B | +4.6% |
| FY 2023 | $40.11B | -8.1% |
| FY 2022 | $43.65B | +1.3% |
| FY 2021 | $43.08B | +24.5% |
| FY 2020 | $34.61B | +8.5% |
| FY 2019 | $31.90B | +4.3% |
| FY 2018 | $30.58B | +11.6% |
| FY 2017 |
ABBOTT LABORATORIES (ABT) reported revenue of $44.33B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, ABBOTT LABORATORIES's revenue grew from $21.41B to $44.33B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $27.39B |
| +31.3% |
| FY 2016 | $20.85B | +2.2% |
| FY 2015 | $20.41B | +0.8% |
| FY 2014 | $20.25B | +3.0% |
| FY 2013 | $19.66B | +3.2% |
| FY 2012 | $19.05B | -11.0% |
| FY 2011 | $21.41B | - |